Syngene International logo

Syngene International

SYNGENE NSE

Key Fundamentals

SmallcapHealthcare TechnologyHealthcare
Market Cap
₹15,204 Cr
Volatility
Moderate
P/E Ratio
69.7
EBITDA
₹989 Cr
Return on Equity
6.54%
Debt to Equity
0.09
Book Value
₹119.9
EPS
₹11.85
52W High
₹678.95
52W Low
₹375.25

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Strengths

2
  • Company has reduced debt.
  • Company is almost debt free.

Weaknesses

4
  • Stock is trading at 3.19 times its book value
  • The company has delivered a poor sales growth of 11.4% over past five years.
  • Company has a low return on equity of 10.1% over last 3 years.
  • Dividend payout has been low at 12.0% of profits over last 3 years

Growth Rate

Revenue Growth
2.56% lower than 3Y
Net Income Growth
-36.17% lower than 3Y
Cash Flow Change
-21.62% lower than 3Y
ROE
-37.71% lower than 3Y
ROCE
-36.74% higher than 3Y
EBITDA Margin (Avg.)
-13.38% higher than 3Y

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 2d ago
AI opinion · based on fundamentals
Risk high

Syngene International trades at a market cap of ₹15,204 Cr with a PE of 70.2x and a price-to-book of 3.2x. The company is nearly debt-free but faces headwinds with TTM sales declining 3% and TTM profit falling 42%, while its 3-year ROE stands at 10% and the stock has lost 42% over the past year.

Bull Case 7
  • The company is almost debt-free, significantly reducing financial risk and interest burden
  • Company has actively reduced debt, strengthening balance sheet resilience in a capital-intensive CDMO industry
  • 5-year compounded sales CAGR of 11% indicates a reasonable medium-term revenue growth trajectory
  • 3-year compounded sales CAGR of 5% shows the business continues to grow despite recent slowdowns
  • Dividend yield of 0.33% provides a small but consistent return to shareholders, signaling cash flow stability
  • 5-year ROE averaging 11% reflects the company's ability to generate reasonable returns on equity over a longer cycle
  • 10-year stock CAGR of 5% shows the company has created some long-term value for shareholders despite recent corrections
Bear Case 8
  • PE ratio of 70.2x is extremely elevated, implying the stock is priced for significant future growth that current fundamentals do not support
  • TTM compounded profit has declined 42%, indicating a severe deterioration in earnings
  • TTM sales have contracted by 3%, showing the topline is currently shrinking rather than growing
  • Last year ROE dropped to 8% from a 3-year average of 10%, signaling declining capital efficiency
  • Stock has fallen 42% over the past 1 year and 23% CAGR decline over 3 years, reflecting sustained negative price momentum
  • Price-to-book of 3.2x is high relative to the modest ROE of 10%, suggesting the valuation premium may not be justified by returns generated
  • Dividend payout ratio of only 12% of profits over the last 3 years limits direct shareholder returns
  • 5-year compounded profit CAGR of 0% means the company has delivered zero profit growth over half a decade

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 2h ago
Positives 2
  • Renewable energy stake acquired Aug 24

    Syngene invested ₹2.52 crore for a 12.44% stake in Ampin C&I Power Twelve Pvt Ltd to secure captive renewable power and support decarbonization goals.

  • FY26 final dividend remitted Sep 10

    Syngene commenced remittance of ₹1.25 per share final dividend for FY26 to shareholders on record as of June 26, 2026.

Neutral 3
  • Kotak investor meet Sep 17 Sep 12

    Syngene will participate in the Healthcare Forum 2026 organized by Kotak in Mumbai on September 17, with group and one-on-one sessions. No UPSI to be disclosed.

  • Goldman Sachs Asia conference Aug 25

    Syngene will attend the Goldman Sachs Asia Leaders Conference 2026 in Hong Kong on August 31 to September 1. No UPSI disclosure planned.

  • Entrust Family Office meet Aug 24

    Syngene scheduled a virtual one-on-one meeting with Entrust Family Office on August 28, 2026 at 12:00 pm. No UPSI to be disclosed.

TL;DR: Syngene shows steady shareholder engagement with active participation in multiple investor conferences (Kotak, Goldman Sachs, Entrust) and timely FY26 dividend remittance of ₹1.25/share. The ₹2.52 crore renewable energy investment signals a forward-looking ESG commitment. No headwinds are visible in the recent news flow, and the trend appears stable with consistent institutional outreach suggesting management confidence in the company's outlook.

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
808
910
854
917
790
891
944
1,018
875
911
917
1,037
736
Expenses
596
656
622
600
620
646
660
674
668
711
708
733
645
Operating Profit
212
254
232
317
170
245
284
344
206
200
209
303
90.8
OPM %
26.22%
27.92%
27.12%
34.56%
21.5%
27.47%
30.05%
33.75%
23.6%
21.91%
22.81%
29.27%
12.34%
Other Income
23.6
14.2
25.6
16.1
50.1
16.5
18.3
18.9
17.7
15.4
-55.2
16.2
11.8
Interest
10.5
13
10.8
12.9
11.7
13.1
12.4
15.9
11.6
13.2
11.9
12.1
9.6
Depreciation
102
105
108
111
107
111
109
106
111
117
114
112
112
PBT
123
151
138
209
101
137
181
241
101
85.2
28.4
196
-19.2
Tax %
24%
22.69%
19.32%
9.76%
25.27%
22.72%
27.49%
23.78%
14.41%
21.24%
47.18%
24.54%
-53.12%
Net Profit
93.4
117
112
189
75.7
106
131
183
86.7
67.1
15
148
-9
EPS in Rs
2.32
2.9
2.77
4.69
1.88
2.64
3.26
4.55
2.15
1.67
0.37
3.67
-0.22
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
1,423
1,826
2,012
2,184
2,604
3,193
3,489
3,642
3,739
3,600
Expenses
949
1,289
1,394
1,507
1,861
2,251
2,472
2,598
2,817
2,797
Operating Profit
474
537
618
678
743
942
1,017
1,045
921
803
OPM %
33%
29%
31%
31%
29%
30%
29%
29%
25%
22%
Other Income
53
75
153
94
75
63
77
101
-9
-12
Interest
23
32
35
28
24
45
47
53
49
47
Depreciation
131
164
219
274
310
366
426
433
453
454
PBT
372
415
517
469
484
594
621
660
411
290
Tax %
18%
20%
20%
14%
18%
22%
18%
25%
23%
—
Net Profit
305
332
412
405
396
464
510
496
317
221
EPS in Rs
7.64
8.29
10.3
10.12
9.88
11.57
12.69
12.33
7.86
5.49
Div. Payout %
7%
3%
0%
0%
10%
11%
10%
10%
16%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
200
200
400
400
401
401
402
402
403
Reserves
1,520
1,768
1,776
2,421
2,897
3,217
3,856
4,324
4,436
Borrowings
787
813
773
893
1,022
815
555
578
458
Other Liabilities
681
922
1,214
1,169
1,245
1,398
1,339
1,491
1,757
Total Liabilities
3,189
3,704
4,163
4,883
5,564
5,831
6,152
6,796
7,055
Fixed Assets
1,030
1,377
2,020
2,201
2,393
2,667
2,850
2,802
3,000
CWIP
155
274
234
237
346
177
838
1,266
1,046
Investments
158
716
776
702
1,034
918
548
647
741
Other Assets
1,846
1,337
1,133
1,743
1,790
2,069
1,916
2,081
2,268
Total Assets
3,189
3,704
4,163
4,883
5,564
5,831
6,152
6,796
7,055
Figures in ₹ Crores

Cash Flow

Particulars Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
446
630
677
701
581
824
1,042
1,168
915
Investing
-349
-646
-424
-629
-611
-653
-494
-744
-839
Financing
-79
-72
-226
58
-31
-342
-551
-142
-215
Net Cash Flow
18
-88
28
130
-62
-172
-4
281
-138
Free Cash Flow
82
47
34
255
105
305
553
398
547
CFO/OP
111
135
127
116
92
102
115
123
107
Figures in ₹ Crores

Ratios

Particulars Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
68
68
72
79
71
61
46
53
50
Inventory Days
82
30
18
41
87
141
94
60
56
Days Payable
195
154
156
167
113
109
100
136
138
Cash Conversion Cycle
-44
-56
-66
-47
45
92
40
-23
-32
Working Capital Days
-48
-103
-172
-66
-43
-14
-27
-51
-68
ROCE %
—
17%
17%
14%
13%
15%
15%
13%
10%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Syngene International insights

63 extracted metrics + investor summaries across FY11–FY27.

Log in — free

Shareholding Pattern

Others1.44%Promot.52.59%Public6.14%FIIs11.82%DIIs28.02%As ofJun 2026

Documents

Frequently Asked Questions about Syngene International

What does Syngene International Ltd do?
Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). Total research & manufactu...
Where is Syngene International Ltd (SYNGENE) listed?
Syngene International Ltd trades as SYNGENE on the NSE and under code 539268 on the BSE.
Which sector does Syngene International Ltd belong to?
Syngene International Ltd is classified under the Healthcare sector, in the Healthcare Services industry.
What is the market capitalisation of Syngene International Ltd?
Syngene International Ltd has a market capitalisation of ₹15,204 Cr, which places it in the Mid Cap band.
What is the PE ratio of Syngene International Ltd?
Syngene International Ltd trades at a PE ratio of 69.70, on earnings per share of ₹11.85, against a book value of ₹119.9 per share.
What is the 52-week high and low of Syngene International Ltd?
Over the last 52 weeks Syngene International Ltd has traded between ₹375.25 and ₹678.95.
Does Syngene International Ltd pay dividends?
Syngene International Ltd has a dividend yield of 0.33%.
What is the Return on Equity (ROE) of Syngene International Ltd?
Syngene International Ltd reported a return on equity of 6.54%. Its debt-to-equity ratio is 0.09.

Company Information

Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). Total research & manufacturing infrastructure for the company is spread across 1.9 million square feet across locations. [1]

Website syngeneintl.com
CEO Mr. Peter James Jonathan Bains
Employees 6,533
Listed 2015-08-11
Face Value ₹ 10
Issued Size 40,29,39,420

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/SYNGENE.md for Syngene International Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List